Price T Rowe Associates Inc Kezar Life Sciences, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 83,600 shares of KZR stock, worth $47,651. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,600
Previous 47,674
75.36%
Holding current value
$47,651
Previous $43,000
18.6%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding KZR
# of Institutions
83Shares Held
39.6MCall Options Held
3.2KPut Options Held
700-
Suvretta Capital Management, LLC New York, NY7.17MShares$4.09 Million0.18% of portfolio
-
Avidity Partners Management LP Dallas, TX5.03MShares$2.86 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.74MShares$1.56 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L32.05MShares$1.17 Million0.18% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.93MShares$1.1 Million0.03% of portfolio
About Kezar Life Sciences, Inc.
- Ticker KZR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,369,504
- Market Cap $39M
- Description
- Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...